What is an ovarian granulosa cell tumour?
An ovarian granulosa cell tumour is a rare cancer that starts in the granulosa cells of the ovary. In a healthy ovary, these cells surround each developing egg and make the female hormone oestrogen. Granulosa cell tumours belong to the group of sex cord-stromal tumours, and they are the most common malignant tumour in that group.
There are two distinct types. The adult type makes up about 95% of cases and usually affects women around and after the menopause. The juvenile type makes up about 5% and mostly affects girls and young women under 30.
Because the tumour cells often produce oestrogen, the first sign is frequently unusual vaginal bleeding or, in young girls, early puberty. Most tumours are found while still confined to one ovary and can be cured with surgery. The adult type, however, is known for coming back many years, even decades, later, so long-term follow-up is essential.
1. How common is it?
| Feature | Details |
|---|---|
| Share of ovarian cancers | About 2-5% of all ovarian cancers |
| Incidence | About 0.5-1.6 per 100,000 women per year; 0.61 per 100,000 per year in a Dutch nationwide registry study of 1,031 patients |
| Adult vs juvenile | Adult type about 95%, juvenile type about 5% |
| Age (adult type) | Wide range, but most often 50-55 years; about two-thirds of women are postmenopausal at diagnosis |
| Age (juvenile type) | Average age 13 in a classic series of 125 cases: 44% were 10 or younger and only about 3% were over 30 |
| Laterality | Almost always one ovary only |
| Stage at diagnosis | Most tumours (roughly 80-90%) are stage I |
2. Types and causes
The two types look different under the microscope, are driven by different gene changes and behave differently over time.
| Feature | Adult type | Juvenile type |
|---|---|---|
| Typical patient | Peri- and postmenopausal women; can occur at any adult age | Girls and young women, mostly under 30 |
| Key gene change | FOXL2 c.402C>G (p.C134W) in about 97% of tumours | AKT1 in-frame duplications (over 60% of tumours in girls under 15) or GNAS mutations (about 30%); FOXL2 C134W only rarely |
| Main hormone effect | Oestrogen excess: bleeding, endometrial hyperplasia or cancer | Oestrogen excess: early puberty in children, menstrual changes in young women |
| Usual course | Slow-growing, but can recur 5, 10 or more than 30 years later | Usually cured if confined to the ovary; advanced or ruptured tumours tend to recur early, often within 3 years |
2.1 The FOXL2 mutation in the adult type
In 2009, researchers in Vancouver found a single, identical change in the FOXL2 gene in 86 of 89 adult granulosa cell tumours (97%). The change swaps one DNA letter (402C>G), which replaces the amino acid cysteine with tryptophan at position 134 of the FOXL2 protein. It is known as FOXL2 C134W.
FOXL2 is a master switch for normal granulosa cell development. The mutation is somatic, which means it arises only in the tumour and is not inherited. Testing for it helps pathologists confirm the diagnosis when the microscope picture is unclear.
A second change, a mutation in the TERT promoter (C228T), is found in about 22% of first tumours and about 41% of recurrent tumours. It appears to be linked to tumour progression and poorer survival.
2.2 Risk factors
The cause of granulosa cell tumours is not known, and no lifestyle cause has been proven.
- Most cases are sporadic and do not run in families.
- The juvenile type has been reported in girls with Ollier disease and Maffucci syndrome, two rare conditions with multiple benign cartilage tumours.
- Granulosa cell tumours are not part of the usual inherited ovarian cancer syndromes, such as BRCA1 or BRCA2.
3. How does it look?
3.1 The tumour itself
Granulosa cell tumours are usually large, one-sided ovarian masses, often around 10 cm or more across by the time they are removed. The juvenile tumours in the 1984 series measured 3 to 32 cm, with an average of 12.5 cm.
| Feature | Typical appearance |
|---|---|
| Shape and surface | Smooth, rounded or lobulated mass; the surface may have ruptured |
| Cut surface | Mixed solid and cystic, often yellow or tan-grey, sometimes with blood-filled cysts |
| Consistency | Soft to firm; areas of bleeding are common because the tumour has many blood vessels |
| Rupture | Some tumours rupture before or during surgery and can cause bleeding into the abdomen |
3.2 On scans
| Test | Typical findings |
|---|---|
| Transvaginal ultrasound | A solid or multi-cystic mass with a spongy, “Swiss cheese” look and good blood flow; a thickened lining of the womb due to oestrogen |
| MRI of the pelvis | Helps describe the mass and the womb lining before surgery |
| CT of the chest, abdomen and pelvis | Looks for spread in the abdomen and to other organs |
3.3 Under the microscope
| Feature | Adult type | Juvenile type |
|---|---|---|
| Cells | Small, uniform cells with scant cytoplasm | Larger, rounder cells, often with plentiful pale or pink cytoplasm (luteinised) |
| Nuclei | Pale, oval, with a lengthwise groove (“coffee-bean” nuclei) | Dark and round, without grooves |
| Pattern | Many patterns (diffuse, microfollicular, trabecular, insular); small rosette-like spaces called Call-Exner bodies | Mostly diffuse sheets with follicles of irregular size and shape, often containing mucin-like fluid |
| Cell division | Usually low | Often brisk |
Call-Exner bodies are a microscopic feature only; they cannot be seen with the naked eye.
3.4 Special stains and tests
| Test | Typical result | Why it matters |
|---|---|---|
| Inhibin alpha | Positive | Supports a sex cord-stromal tumour |
| Calretinin | Positive | Supports a sex cord-stromal tumour |
| FOXL2 protein (immunostain) | Positive in the nucleus | Marks sex cord-stromal tumours in general, not only the mutated adult type |
| FOXL2 C134W mutation test | Present in about 97% of adult type | Confirms an adult granulosa cell tumour in difficult cases, as recommended by ESMO |
| Keratin and EMA | Usually negative or weak | Helps exclude carcinomas that can look similar |
4. Symptoms
Symptoms come from two sources: the hormones the tumour makes and the size of the mass. The pattern depends strongly on the patient’s age.
4.1 Symptoms of oestrogen excess
| Age group | Typical effects |
|---|---|
| After the menopause | Postmenopausal bleeding, which is often the first sign; breast tenderness |
| Women of reproductive age | Heavy or irregular periods, bleeding between periods, or missed periods |
| Girls before puberty (juvenile type) | Early puberty (isosexual pseudoprecocity): early breast development, vaginal bleeding, pubic hair and a growth spurt. This was the reason for diagnosis in 82% of prepubertal girls in the 1984 series |
Long exposure to tumour-made oestrogen also affects the womb lining (endometrium). In a Dutch study of 1,031 women, 25.5% had endometrial hyperplasia (overgrowth of the lining) and 5.9% had endometrial cancer at the time the granulosa cell tumour was diagnosed. These endometrial cancers are usually early and low grade.
A small number of granulosa cell tumours make male hormones instead, which can cause excess hair growth, acne or a deeper voice.
4.2 Symptoms of the mass
- Pain, pressure or a feeling of fullness in the lower abdomen or pelvis.
- Swelling of the abdomen or a lump that can be felt.
- Needing to pass urine more often, or constipation, when the mass presses on the bladder or bowel.
- Fluid in the abdomen (ascites) in a minority of patients.
4.3 Sudden severe pain: an emergency
Granulosa cell tumours have many blood vessels and can rupture or bleed into the abdomen. This causes sudden severe abdominal pain, dizziness and low blood pressure. In young women it can mimic an ectopic pregnancy and needs emergency surgery.
When to see a doctor: any bleeding after the menopause, new irregular bleeding, signs of puberty in a young child, or a persistent swelling or pain in the lower abdomen should be checked promptly.
5. Diagnosis
5.1 Examination and imaging
The doctor examines the abdomen and pelvis and arranges a transvaginal or abdominal ultrasound. CT or MRI is used to define the mass and look for spread, as recommended in the ESMO guideline.
5.2 Blood tests (tumour markers)
| Marker | What it shows | Notes |
|---|---|---|
| Inhibin B | Made by granulosa cells | The most accurate single marker in a Finnish study; useful for diagnosis and for spotting recurrence |
| Anti-Mullerian hormone (AMH) | Also made by granulosa cells | Raised levels are very specific for granulosa cell tumours in postmenopausal women or after the ovaries are removed. Combined with inhibin B, it reached 100% sensitivity and 93% specificity in distinguishing these tumours from endometriomas |
| Inhibin A | Sometimes raised | Less useful than inhibin B |
| Oestradiol | May be raised | Not reliable, because not every tumour makes it and levels change with the menstrual cycle |
| CA-125 and HE4 | Usually normal or low | Help distinguish the tumour from epithelial ovarian cancer |
| AFP, hCG and LDH | Normal in granulosa cell tumours | Checked in young patients to rule out germ cell tumours |
In premenopausal women, inhibin B and AMH can also be produced by the healthy ovary, so results must be interpreted with care.
5.3 Checking the womb lining
Because of the link with endometrial hyperplasia and cancer, the endometrium must be sampled (biopsy, hysteroscopy or curettage) in any woman whose womb is kept. If the womb is removed, it is examined by the pathologist.
5.4 Confirming the diagnosis
The final diagnosis is made by a pathologist after the tumour is removed. A review by an expert gynaecological pathologist is advised. Stains for inhibin, calretinin and FOXL2, plus the FOXL2 mutation test, can confirm the diagnosis in uncertain cases.
6. Stages
Granulosa cell tumours are staged with the same FIGO (2014) system used for other ovarian cancers. Staging is based on what the surgeon and pathologist find.
| Stage | Description |
|---|---|
| IA | Tumour in one ovary, capsule intact, no tumour on the surface, washings negative |
| IB | Tumour in both ovaries, capsules intact |
| IC1 | Tumour limited to the ovary or ovaries, but the capsule ruptured during surgery (surgical spill) |
| IC2 | Capsule ruptured before surgery, or tumour on the ovarian surface |
| IC3 | Cancer cells in ascites or peritoneal washings |
| II | Spread within the pelvis, for example to the womb, tubes or other pelvic tissues |
| III | Spread to the lining of the abdomen beyond the pelvis and/or to lymph nodes behind the abdomen |
| IV | Distant spread, for example fluid around the lungs with cancer cells or spread into the liver |
Most granulosa cell tumours are stage I at diagnosis. Spread to lymph nodes is very uncommon.
7. Treatment
Treatment should be planned by a specialist gynaecological oncology team. Surgery is the main treatment, and for most patients with stage IA disease it is the only treatment needed.
7.1 Surgery
| Situation | Usual operation |
|---|---|
| Postmenopausal women, or no wish for future pregnancy | Removal of the womb and both ovaries and tubes (hysterectomy and bilateral salpingo-oophorectomy) with staging |
| Young women and girls with stage I disease who wish to keep fertility | Fertility-sparing surgery: removal of the affected ovary and tube (unilateral salpingo-oophorectomy), keeping the womb and the other ovary, plus staging and endometrial sampling |
| Advanced or bilateral disease | Hysterectomy, removal of both ovaries and removal of as much visible tumour as possible (debulking) |
Key points from the ESMO guideline and large series:
- Staging includes inspection of the whole abdomen, peritoneal washings, removal of the omentum and biopsies of the peritoneum.
- Lymph node removal is not needed routinely, because node spread is very rare in early disease.
- Avoiding rupture matters. Tumour rupture was the strongest predictor of recurrence in a Finnish study of molecularly confirmed adult tumours.
- Removing the whole ovary is preferred to removing only the cyst. Simple cystectomy has been linked to more recurrences.
- In juvenile tumours, the safety of fertility-sparing surgery in stage IC2 or IC3 disease is less certain.
7.2 Chemotherapy
| Stage | Usual approach |
|---|---|
| IA | Surgery alone; no further treatment needed |
| IC (adult type) | Observation for most; chemotherapy can be discussed for IC2-IC3, which recur more often than IC1 |
| IC (juvenile type) | Chemotherapy is often considered |
| II-IV | Platinum-based chemotherapy after surgery |
| Recurrence | Surgery if possible; chemotherapy, hormonal therapy or trials |
The main regimens are:
| Regimen | Schedule | Notes |
|---|---|---|
| BEP (bleomycin, etoposide, cisplatin) | Usually 3 cycles | The most widely used combination. Side effects include lung damage from bleomycin, hearing loss, nerve damage and kidney strain. ESMO advises avoiding bleomycin in people over 40 or with lung disease |
| Carboplatin and paclitaxel | Usually 6 cycles | Easier to tolerate, especially for older women. Side effects include hair loss, numbness in the hands and feet and low blood counts |
The NRG/GOG-0264 randomised trial (published 2024) compared the two regimens in 63 patients, 87% of whom had granulosa cell tumours. Carboplatin-paclitaxel did not meet the statistical test for non-inferiority, but median progression-free survival was 27.7 months with carboplatin-paclitaxel and 19.7 months with BEP. Severe side effects were less frequent with carboplatin-paclitaxel (77% vs 90%), and the authors concluded that both regimens may be considered.
For relapse after platinum, the ALIENOR trial established weekly paclitaxel as a standard option. Adding bevacizumab raised the response rate (44% vs 25%) but did not improve the 6-month progression-free rate (72% vs 71%).
7.3 Hormonal therapy
Granulosa cell tumours often carry oestrogen and progesterone receptors and depend on the oestrogen pathway. Hormonal therapy is therefore an option, mainly for recurrent or advanced adult-type tumours.
| Medicine | How it works | Main side effects |
|---|---|---|
| Aromatase inhibitors (letrozole, anastrozole) | Block oestrogen production | Hot flushes, joint pain, bone thinning |
| Progestins (e.g. megestrol acetate) | Counteract oestrogen | Weight gain, fluid retention, blood clots |
| GnRH agonists (e.g. leuprorelin) | Switch off hormone signals from the pituitary | Menopausal symptoms |
| Tamoxifen | Blocks oestrogen receptors | Hot flushes; risk of blood clots and womb changes |
The evidence is limited. A 2014 review of 31 patients reported a pooled response rate of 71%, but the studies were small and of poor quality. In the first prospective trial, PARAGON (2021), anastrozole controlled the disease in 78.9% of patients at 12 weeks, yet only about 10% had real shrinkage, and median progression-free survival was 8.6 months.
Hormone replacement therapy (HRT) containing oestrogen is generally avoided after a granulosa cell tumour, as advised by ESMO.
7.4 Treatment of recurrence
- Repeat surgery to remove all visible tumour is the most effective treatment when feasible, and many patients have several operations over the years.
- Chemotherapy: platinum combinations, weekly paclitaxel and other regimens.
- Hormonal therapy, especially for slowly growing disease.
- Radiotherapy may be used for selected localised recurrences or to relieve symptoms.
- Clinical trials of new targeted treatments.
8. Outlook
The outlook is generally good, especially for stage I disease. The main challenge of the adult type is its tendency to recur late.
| Factor | What the evidence shows |
|---|---|
| Overall survival | 96.5% at 5 years and 94.1% at 10 years in a Taiwanese series of 176 adult-type tumours |
| By stage | Reported 5-year survival of about 75-95% for stage I, 55-75% for stage II and 22-50% for stages III-IV |
| Recurrence (adult type) | About 1 in 4 to 1 in 3 women. In a Helsinki study with a median follow-up of 15.5 years, 32% relapsed |
| Timing of recurrence | Median time to first relapse about 4-7 years; 75% of relapses within 10 years; reported up to 37 years after diagnosis |
| After recurrence | Many patients live for years with treatment; in the Helsinki study, 48% of women who relapsed eventually died of the disease, at a median of 15.3 years |
| Juvenile type | 92% were alive and free of disease in the 1984 series. Most stage I tumours are cured, but advanced or ruptured tumours can recur and prove fatal within about 3 years |
Factors linked to a higher risk of recurrence include higher stage, tumour rupture, stage IC2-IC3, residual tumour after surgery and large tumour size.
9. Follow-up and living with the condition
9.1 Follow-up
Because recurrence can happen very late, follow-up should be long-term. ESMO recommends check-ups with examination and tumour markers every 6 months from the third year onwards, continued indefinitely.
| Part of follow-up | Details |
|---|---|
| Examination | Including pelvic examination and review of symptoms |
| Tumour markers | Inhibin B and AMH; a rising level can signal a recurrence before symptoms appear |
| Pelvic ultrasound | Every 6 months after fertility-sparing surgery |
| CT or MRI | When symptoms or rising markers suggest recurrence |
Nearly half of recurrences in the Helsinki study caused no symptoms. This makes regular marker checks particularly valuable.
9.2 Fertility and pregnancy
Fertility-sparing surgery allows many young women and girls to have children later. When chemotherapy is planned, egg or embryo freezing can be discussed beforehand. Women who keep one ovary need regular ultrasound and marker checks, and some choose to have the remaining ovary and womb removed once their family is complete.
9.3 Everyday life
- Report any new bleeding, pelvic pain or abdominal swelling promptly, even many years after treatment.
- Ask your team before taking any hormone-containing medicine, including HRT.
- Women who have had both ovaries removed before the menopause may need advice on bone health and menopausal symptoms.
- Specialist nurses and ovarian cancer support organisations can help with practical and emotional concerns.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is a granulosa cell tumour the same as ordinary ovarian cancer? | No. Most ovarian cancers are epithelial cancers. Granulosa cell tumours arise from hormone-producing cells, grow more slowly and are treated differently |
| Is it inherited? | Almost never. The FOXL2 mutation arises only in the tumour and is not passed on to children |
| Can I still have children? | Often yes. Young women with stage I disease can usually keep the womb and the other ovary |
| Why do I need follow-up for so long? | The adult type can come back 10, 20 or even more than 30 years after the first operation |
| Will the bleeding stop after surgery? | Usually, because the source of excess oestrogen is removed. Any later bleeding should be checked |
| Can my daughter’s early puberty be reversed? | After the tumour is removed, oestrogen levels fall and most signs of early puberty settle |
Resources
- WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Shah, S.P. et al. (2009) ‘Mutation of FOXL2 in granulosa-cell tumors of the ovary’, New England Journal of Medicine, 360(26), pp. 2719-2729.
- Kommoss, S. et al. (2014) ‘A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary’, Histopathology, 64(3), pp. 380-388.
- Pilsworth, J.A. et al. (2018) ‘TERT promoter mutation in adult granulosa cell tumor of the ovary’, Modern Pathology, 31(7), pp. 1107-1115.
- Young, R.H., Dickersin, G.R. and Scully, R.E. (1984) ‘Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases’, American Journal of Surgical Pathology, 8(8), pp. 575-596.
- Kalfa, N. et al. (2006) ‘Activating mutations of the stimulatory G protein in juvenile ovarian granulosa cell tumors: a new prognostic factor?’, Journal of Clinical Endocrinology and Metabolism, 91(5), pp. 1842-1847.
- Bessière, L. et al. (2015) ‘A hot-spot of in-frame duplications activates the oncoprotein AKT1 in juvenile granulosa cell tumors’, EBioMedicine, 2(5), pp. 421-431.
- Schumer, S.T. and Cannistra, S.A. (2003) ‘Granulosa cell tumor of the ovary’, Journal of Clinical Oncology, 21(6), pp. 1180-1189.
- Ray-Coquard, I. et al. (2018) ‘Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 29(Suppl 4), pp. iv1-iv18.
- Prat, J. (2014) ‘Staging classification for cancer of the ovary, fallopian tube, and peritoneum’, International Journal of Gynecology and Obstetrics, 124(1), pp. 1-5.
- van Meurs, H.S. et al. (2013) ‘The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study’, International Journal of Gynecological Cancer, 23(8), pp. 1417-1422.
- Haltia, U.M. et al. (2017) ‘Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors’, Gynecologic Oncology, 144(1), pp. 83-89.
- Lane, A.H. et al. (1999) ‘Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors’, Gynecologic Oncology, 73(1), pp. 51-55.
- Färkkilä, A. et al. (2017) ‘Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary’, Annals of Medicine, 49(5), pp. 435-447.
- Bryk, S. et al. (2016) ‘Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors’, Gynecologic Oncology, 143(3), pp. 571-577.
- Gan, J. et al. (2025) ‘Stage IA and IC adult granulosa cell tumors: clinical features, long-term outcomes and prognostic factors in a 333-patient cohort over three decades’, International Journal of Clinical Oncology, 30(12), pp. 2643-2651.
- Brown, J. et al. (2024) ‘Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent chemonaive stromal ovarian tumors: an NRG Oncology/Gynecologic Oncology Group study’, Gynecologic Oncology, 190, pp. 283-290.
- Ray-Coquard, I. et al. (2020) ‘Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial’, JAMA Oncology, 6(12), pp. 1923-1930.
- van Meurs, H.S. et al. (2014) ‘Hormone therapy in ovarian granulosa cell tumors: a systematic review’, Gynecologic Oncology, 134(1), pp. 196-205.
- Banerjee, S.N. et al. (2021) ‘A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: the PARAGON/ANZGOG 0903 trial’, Gynecologic Oncology, 163(1), pp. 72-78.
- Sun, H.D. et al. (2012) ‘A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors’, Gynecologic Oncology, 124(2), pp. 244-249.
- Zhuang, Y. et al. (2022) ‘Can adjuvant chemotherapy improve the prognosis of adult ovarian granulosa cell tumors?’, Medicine, 101(11), e29062.
- Hines, J.F. et al. (1996) ‘Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature’, Gynecologic Oncology, 60(3), pp. 484-488.
- National Cancer Institute (2026) Granulosa cell tumor. NCI Dictionary of Cancer Terms. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/granulosa-cell-tumor (Accessed: October 2026).
Prepared by the editorial team, October 2026.